Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use

© 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within t...

Full description

Saved in:
Bibliographic Details
Main Authors: Yohei Sotomi, Pannipa Suwannasom, Erhan Tenekecioglu, Hiroki Tateishi, Mohammad Abdelghani, Patrick W. Serruys, Yoshinobu Onuma
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/44884
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-44884
record_format dspace
spelling th-cmuir.6653943832-448842018-04-25T07:57:21Z Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use Yohei Sotomi Pannipa Suwannasom Erhan Tenekecioglu Hiroki Tateishi Mohammad Abdelghani Patrick W. Serruys Yoshinobu Onuma Agricultural and Biological Sciences © 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use. 2018-01-24T04:49:29Z 2018-01-24T04:49:29Z 2015-01-01 Journal 17448344 14779072 2-s2.0-84942627294 10.1586/14779072.2015.1089172 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44884
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Agricultural and Biological Sciences
spellingShingle Agricultural and Biological Sciences
Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Hiroki Tateishi
Mohammad Abdelghani
Patrick W. Serruys
Yoshinobu Onuma
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
description © 2015 Informa UK, Ltd. Drug-eluting stents have significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, neoatherosclerosis, permanent impairment of the physiological vasomotor function and interference with potential future grafting of the stented segment. Bioresorbable scaffolds have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress and mechanotransduction. This article presents a comparison between the most widespread bioresorbable vascular scaffold 'Absorb BVS' and second-generation drug-eluting stent (cobalt chromium everolimus-eluting stent) from bench to clinical use.
format Journal
author Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Hiroki Tateishi
Mohammad Abdelghani
Patrick W. Serruys
Yoshinobu Onuma
author_facet Yohei Sotomi
Pannipa Suwannasom
Erhan Tenekecioglu
Hiroki Tateishi
Mohammad Abdelghani
Patrick W. Serruys
Yoshinobu Onuma
author_sort Yohei Sotomi
title Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_short Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_full Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_fullStr Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_full_unstemmed Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
title_sort differential aspects between cobalt-chromium everolimus drug-eluting stent and absorb everolimus bioresorbable vascular scaffold: from bench to clinical use
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84942627294&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/44884
_version_ 1681422642337284096